REDUCE-AMI
Randomized Evaluation of Decreased Usage of Beta-Blockers after Acute Myocardial Infarction
Paciente / Población Intervención / Exposición Comparación Desenlace
In 5,020 patients after acute MI with preserved LVEF (≥50%), beta-blocker therapy did not reduce all-cause death or new MI compared with no beta-blocker.
N
5020
Diseño
Registry-based open-label RCT
Desenlace
Death from any cause or new myocardial infarction
Relevancia
2
ResultadoBeta-blocker 7.9% vs no beta-blocker 8.3% (HR 0.96, 95% CI 0.79-1.16, P=0.64); neutral over median ~3.5 years in post-MI patients with LVEF ≥50%.
Yndigegn T, et al. N Engl J Med. 2024;390(15):1372-81. 10.1056/NEJMoa2401479
Discusión y crítica
Open-label with lower-than-expected event rates in a well-revascularised population. First modern RCT to challenge routine beta-blockade after MI with preserved EF and, with REBOOT, shifting guidelines.